Compare T-Mobile Us Inc (TMUS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Mobile Us Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? T-Mobile Us Inc trades at $190.56 (market cap $211.72B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and T-Mobile Us Inc pays a 2.09% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TMUS | VRTX | |
|---|---|---|
Market Cap | $211.72B | $121.95B |
Sector | Media | Health |
52-Week High | $259.01 | $529.59 |
52-Week Low | $167.65 | $366.54 |
Enterprise Value | $329.42B | $116.69B |
Dividend Yield | 2.09% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
